New cocktail of chemo and antibodies shows promise against aggressive stomach cancer
NCT ID NCT01191697
First seen Nov 03, 2025 · Last updated Jun 23, 2026 · Updated 38 times
Summary
This phase 2 trial tested a combination of two chemotherapy drugs (capecitabine and oxaliplatin) plus two targeted antibodies (bevacizumab and trastuzumab) in 37 people with HER2-positive stomach or esophageal cancer that had spread. The goal was to see how safe and effective the combo was at shrinking tumors. Results showed that many patients had their tumors shrink, and the treatment helped control the disease for a time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
capecitabine, oxaliplatin, bevacizumab (Avastin), trastuzumab (Herceptin)
What this could lead to
If successful, this combination could offer a new treatment option that shrinks tumors and extends life for people with HER2-positive stomach or esophageal cancer that has spread.
What could go wrong
This is a small, early-phase trial with only 37 participants, so results may not apply to everyone. Combining multiple drugs also raises the risk of side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.